NAZEM FARZAD 4

What Happened

• Nazem Farzad, a director of Nautilus Biotechnology, was granted a derivative award covering 45,000 shares on 2026-06-18. The reported acquisition price is $0.00 (derivative grant), so no cash was paid at grant.
• The grant is described in the filing as an Option under the Issuer’s 2021 Equity Incentive Plan and is subject to vesting (see footnote). This is a grant/award (not a sale or open-market purchase).

Key Details

• Transaction date: 2026-06-18. Form 4 filed: 2026-06-22 (timely filed within the two-business-day window).
• Amount: 45,000 shares; reported price: $0.00; transaction code: A (award/grant/other acquisition); derivative securities.
• Vesting: Per footnote F1, subject to the reporting person’s continuous status as a “Service Provider,” one-twelfth (1/12th) of the shares subject to the Option vests monthly following the grant date (same day each month or last day if no corresponding day).
• Shares owned after transaction: not disclosed in the provided filing details.
• Accession (filing) reference: 0001234663-26-000002.

Context

• This is a derivative award (option) that vests over time; it does not represent an immediate open-market purchase of shares. The economic value to the insider depends on future share price and satisfying vesting/service conditions.
• Grants are routine compensation/retention tools and do not by themselves indicate a buy or sell signal; they differ from immediate purchases (which can be interpreted as a direct bullish signal).